The work by UB neuroscientists provides key insight into how the “lifesaving” medication offers almost instant relief of symptoms of major depression.
Robust firmonertinib monotherapy activity in front-line EGFR PACC mutant NSCLC including in patients with brain metastasesTop-line pivotal data ...
The Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, ...
Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass., Nov. 14, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology ...
Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains on Track for Q4 2024 - - Data from the Phase 2a Trial of SLS009 in Relapse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback